FDA | mecfa 3/3

MECFA Blog

Cystic Fibrosis Treatment Approved for Use in Children Aged 2 to 5 Years

Officials with the FDA have updated the label of lumacaftor/ivacaftor (Orkambi, Vertex Pharmaceuticals), approving the treatment's use in...

Vertex Pharma (VRTX) Receives European CHMP Positive Opinion for SYMKEVI for People with CF Aged 12

Vertex Pharmaceuticals (Europe) Limited (Nasdaq: VRTX), today announced that the European Medicines Agency’s (EMA) Committee for...

Toothpaste ingredient may bust up cystic fibrosis biofilms

A common antibacterial substance in toothpaste may combat life-threatening diseases such as cystic fibrosis when combined with an with an...

Corbus Pharma (CRBP) Reports Agreement with FDA on Phase 2b Cystic Fibrosis Study Design with Pulmon

Multi-national Phase 2b is designed to provide clear evidence of clinical benefit of lenabasum (formerly known as anabasum) in patients...

New Combination Therapy for Cystic Fibrosis

A new combination of cystic fibrosis transmembrane conductance regulator (CFTR) modulators, tezacaftor and ivacaftor, proved effective...

Introduction of New Therapies Affects Pregnancy Rates in Women With CF, Study Reports

The overall rate at which women with cystic fibrosis are becoming pregnant dropped slightly in recent years — coinciding with the...

Disease Duration, Flare-ups Affect Mental Health of Non-CF Bronchiectasis Patients, Study Finds

VERTEX’S CF BLOCKBUSTER TRIKAFTA EFFECTIVE IN KIDS 6 TO 11 YEARS OF AGE

A case for improved carrier screening

Vertex to Seek Expanded FDA Approval for Trikafta After Positive Child Safety Data

Vertex’s Kaftrio approved for use in Europe and made accessible on the NHS

Age May Affect Outcomes in Lung Transplant Recipients With Cystic Fibrosis

CFF Funding Will Further ContraFect’s Research Into Alternative for Antibiotics

The search for molecular glue in targeted disease control

Vest Therapy Lowers Risk of Hospitalization in Non-CF Bronchiectasis, Study Says

Harvard is working with Boston hospitals to test existing cystic fibrosis drug to help coronavirus p

Annual Scientific Conference

The Heartbreaking Reality of Cystic Fibrosis Care in Iraq: A Mother's Plea for Help

MECFA supports CF patients in Tunisia

International disparities in diagnosis and treatment access for cystic fibrosis

Philip Hopewell Prize for Global Respiratory Health Research

South Africans take on big pharma for access to ‘miracle’ cystic fibrosis drug

MECFA launches campaign to help people with CF in Gaza and the West Bank, Palestine

Ministry of Health unveils national electronic registry for cystic fibrosis patients

MECFA Jordan Project report

Conquering chronic lung infection in cystic fibrosis patients